Published Date:2023-11-10 Original Link:https://www.onenessbio.com/en/news_detail250_1.htm No 1 Date of announcement 2023/11/10 Time of announcement 17:20:22 Subject Oneness Biotech Co., Ltd. receives a Hong Kong patent titled “TOPICAL FORMULATION FOR PROMOTING WOUND HEALING” on Fespixon cream (Research code: ON101). To which item it meets paragraph 53 Date of events 2023/11/10 Statement 1.Date of occurrence of the event:2023/11/10...Read More
Published Date:2023-11-09 Original Link:https://www.onenessbio.com/en/news_detail249_1.htm No 2 Date of announcement 2023/11/09 Time of announcement 20:54:04 Subject FESPIXON, the new drug in treatment of diabetic foot ulcers has been approved as Class 1.1 natural new drug by National Medical Products Administration (NMPA) in China. To which item it meets paragraph 10 Date of events 2023/11/09 Statement 1.Product:FESPIXON,...Read More
Published Date:2023-11-09 Original Link:https://www.onenessbio.com/en/news_detail248_1.htm No 1 Date of announcement 2023/11/09 Time of announcement 16:52:05 Subject The Company’s 2023Q3 consolidated financial statements have been approved by the Board of Directors. To which item it meets paragraph 31 Date of events 2023/11/09 Statement 1. Date of the board of directors submitted or approved:2023/11/09 2. Date of the...Read More
Published Date:2023-10-25 Original Link:https://www.onenessbio.com/en/news_detail247_1.htm No 1 Date of announcement 2023/10/25 Time of announcement 17:07:38 Subject Oneness has submitted medical device registration application of Bonvadis for wound care to the Thai Food and Drug Administration (Thai FDA) in Thailand. To which item it meets paragraph 10 Date of events 2023/10/25 Statement 1. Product:Bonvadis for wound...Read More
Published Date:2023-10-04 Original Link:https://www.onenessbio.com/en/news_detail246_1.htm No 1 Date of announcement 2023/10/04 Time of announcement 17:16:08 Subject The board of directors of the Company approved removal of the noncompete clause for managers. To which item it meets paragraph 21 Date of events 2023/10/04 Statement Date of the board of directors resolution:2023/10/04 Name and title of the managerial...Read More
Published Date:2023-10-02 Original Link:https://www.onenessbio.com/en/news_detail245_2.htm No 1 Date of announcement 2023/10/02 Time of announcement 16:52:23 Subject The Phase 3 MRCT data and the Taiwan real-world cases of the DFU new drug, Fespixon have been accepted for an oral presentation at the 59th EASD To which item it meets paragraph 12 Date of events 2023/10/03 Statement Date...Read More
Published Date:2023-09-25 Original Link:https://www.onenessbio.com/en/news_detail244_2.htm No 1 Date of announcement 2023/09/25 Time of announcement 18:30:26 Subject Oneness has submitted medical device registration application for Bonvadis to the Egyptian Drug Authority (EDA). To which item it meets paragraph 10 Date of events 2023/09/25 Statement 1.Product:Bonvadis for wound care 2.Mass production date:NA 3.Effect on company finances and business:...Read More
Published Date:2023-09-20 Original Link:https://www.onenessbio.com/en/news_detail243_2.htm No 1 Date of announcement 2023/09/20 Time of announcement 16:06:59 Subject Oneness announces the information about the investor’s conference of 2023 Q3 To which item it meets paragraph 12 Date of events 2023/09/27 Statement Date of institutional investor conference:2023/09/27 Time of institutional investor conference:15:00 (GMT+8) Location of institutional investor conference:Online Investor...Read More
Published Date:2023-09-05 Original Link:https://www.onenessbio.com/en/news_detail242_2.htm No 1 Date of announcement 2023/09/05 Time of announcement 16:12:38 Subject The board of directors of the Company approved removal of the noncompete clause for managers. To which item it meets paragraph 21 Date of events 2023/09/05 Statement Date of the board of directors resolution: 2023/09/05 Name and title of the...Read More
